Major Pharmaceutical Company Defined Sample Clauses

Major Pharmaceutical Company Defined. As used in Section 13.1 and 13.2, a “Major Pharmaceutical Company” shall mean any Person that, together with its Affiliates, has [ * ].
AutoNDA by SimpleDocs
Major Pharmaceutical Company Defined. As used in Section 13.1 and 13.2, a "MAJOR PHARMACEUTICAL COMPANY" shall mean any Person that, together with its Affiliates, has [ * ].

Related to Major Pharmaceutical Company Defined

  • Knowledge Defined For purposes of this Agreement, the term “the Company's knowledge” or similar references to knowledge as used herein shall mean in the case of the Members and the Company, the actual knowledge of Rxxxxxx Xxxxxx, Sxx Xxxxxxxx and Jxxx Xxxxxxx after reasonably inquiry.

  • Word Meanings The words such as “herein”, “hereinafter”, “hereof”, and “hereunder” refer to this Agreement as a whole and not merely to a subdivision in which such words appear unless the context otherwise requires. The singular shall include the plural, and vice versa, unless the context otherwise requires. The masculine shall include the feminine and neuter, and vice versa, unless the context otherwise requires.

  • Defined Term Section Action Section 5.11(a) ADS Depositary Section 4.3 Affected Employees Section 5.12(a) Affiliate Section 3.27 Agreement Preamble Antitrust Laws Section 5.4(c) Applicable Laws Section 3.5(a) Assumed Option Section 2.1(c)(iii)(A) Assumed RSU Award Section 2.1(c)(v)(B) Book Entry Share Section 2.1(c)(i) Business Day Section 8.9(k) Cash-Only Shares Section 2.1(c)(i) Certificate of Merger Section 1.1 Class A Ordinary Shares Recitals Class B Ordinary Shares Section 4.3 Closing Section 1.2 Closing Date Section 1.2 Code Section 2.1(c)(iii)(A) Company Preamble Company Acquisition Proposal Section 5.2(a) Company Adverse Recommendation Change Section 5.2(d)(i) Company Benefit Plans Section 3.11(a) Company Certificate Section 2.1(c)(i) Company Common Stock Recitals Company Disclosure Schedule Article 3 Company ESPP Section 5.12(d) Company Material Adverse Effect Section 3.1 Company Material Contract Section 3.23(a) Company Permits Section 3.5(b) Company Permitted Liens Section 3.21(a) Company Preferred Stock Section 3.3 Company Real Property Section 3.5(d) Company Reports Section 3.7(a) Company Representatives Section 5.2(a) Company Restricted Stock Awards Section 2.1(c)(iv) Company Rights Section 2.5 Company Rights Agreement Section 2.5 Company RSU Awards Section 2.1(c)(v) Company Stockholder Approval Section 3.20 Company Stock Option Section 2.1(c)(iii)(A) Company Superior Proposal Section 5.2(d)(ii) Defined Term Section Competition Action Section 5.4(c) Confidentiality Agreement Section 5.2(a) control Section 3.27 Cutoff Date Section 8.9(e) Definitive Financing Agreements Section 5.13(b) Delaware Sub Preamble Deposit Agreement Section 4.3 Derivative Transaction Section 3.25(a) DGCL Recitals Dissenting Shares Section 2.1(c)(vii) Dissenting Stockholder Section 2.1(c)(vii) DLLCA Recitals Effective Time Section 1.1 Environmental Laws Section 3.13(a) ERISA Section 3.11(a) ERISA Affiliate Section 3.11(c) Equity Compensation Exchange Ratio Section 2.1(c)(i) Exchange Act Section 3.4 Exchange Agent Section 2.2(a) Exchange Fund Section 2.2(a) Exchange Ratio Section 2.1(c)(i) Excluded Shares Section 2.1(c)(ii) FCPA Section 3.5(e) Fee Section 7.5(b) Final Parent Stock Price Section 2.1(c)(i) Financing Section 5.13(a) Financing Commitments Section 5.13(a) Financing Sources Section 5.13(a) Form F-6 Section 5.7(a) Form S-4 Section 5.7(a) GAAP Section 3.7(b) Governmental Entity Section 3.6(b) Governmental Official Section 3.5(e) Hazardous Materials Section 3.13(b) HSR Act Section 3.6(b) Indemnified Party(ies) Section 5.11(a) IRS Section 3.11(a) Liens Section 3.4 Material Adverse Effect Section 8.9(c) Merger Recitals Merger Consideration Section 2.1(c)(i) Merger Sub Preamble New Financing Commitments Section 5.13(a) Non-U.S. Antitrust Laws Section 5.4(a)(i) Non-U.S. Company Benefit Plan Section 3.11(a) vi Defined Term Section Non-U.S. Parent Benefit Plan Section 4.11(a) NYSE Recitals OFAC Section 3.5(f) Parent Preamble Parent ADS Recitals Parent Adverse Recommendation Change Section 5.16(d)(i) Parent Alternative Proposal Section 5.16(a) Parent Benefit Plans Section 4.11(a) Parent Disclosure Schedule Article 4 Parent Material Adverse Effect Section 4.1 Parent Material Contract Section 4.23(a) Parent Options Section 4.3 Parent Permits Section 4.5(b) Parent Permitted Liens Section 4.21(a) Parent Real Property Section 4.5(d) Parent Representatives Section 5.16(a) Parent Reports Section 4.7(a) Parent Shareholder Approval Section 4.20 Parent Superior Proposal Section 5.16(d)(ii) Parent UK Prospectus Section 5.7(d)(i) Per Share Cash-Only Additional Cash Amount Section 2.1(c)(i) Per Share Cash Amount Section 2.1(c)(i) Per Share Stock Amount Section 2.1(c)(i) Person Section 3.5(e) PFIC Section 4.10(b) Proxy Statement/Prospectus Section 5.7(a) Regulatory Filings Section 3.6(b) Required Jurisdiction Section 6.1(b)(iii) Returns Section 3.10(a) Rule 16b-3 Section 5.9 Xxxxxxxx-Xxxxx Act Section 3.7(a) SEC Section 3.7(a) Securities Act Section 3.6(b) Significant Subsidiary Section 3.4 Subsidiary Section 8.9(d) Surviving Entity Section 1.1 tax(es) Section 3.10(f) Third Party Provision Section 8.3 to the knowledge of Section 8.9(b) UK FSMA Section 2.2(b)(i) UK Prospectus Rules Section 5.7(d)(i) UKLA Section 5.7(d)(i) U.S. Company Benefit Plan Section 3.11(a) U.S. Parent Benefit Plan Section 4.11(a) AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of February 6, 2011, is by and among Ensco plc, a public limited company organized under the laws of England and Wales (“Parent”), Pride International, Inc., a Delaware corporation (the “Company”), ENSCO Ventures LLC, a Delaware limited liability company and an indirect, wholly owned subsidiary of Parent (“Merger Sub”), and ENSCO International Incorporated, a Delaware corporation and an indirect, wholly-owned subsidiary of Parent (“Delaware Sub”).

  • Defined expressions Words and expressions defined in the Loan Agreement shall have the same meanings when used in this Guarantee unless the context otherwise requires.

  • Good Reason Defined For purposes of this Agreement, the Employee shall have "Good Reason" to terminate his employment during the term of this Agreement only if:

  • PREAMBLE The preamble hereof shall form an integral part of this Agreement.

  • Constructive Termination “Constructive Termination” shall be deemed to occur if (A) there is a material reduction or change in job duties, responsibilities and requirements inconsistent with Executive’s position with the Company and prior duties, responsibilities and requirements, provided that neither a mere change in title alone nor reassignment to a position that is substantially similar to the position held prior to the change in terms of job duties, responsibilities or requirements shall constitute a material reduction in job responsibilities; or (B) there is a reduction in Executive’s then-current base salary by at least twenty percent (20%), provided that an across-the-board reduction in the salary level of all other senior executives by the same percentage amount as part of a general salary level reduction shall not constitute such a salary reduction; or (C) Executive refuses to relocate to a facility or location more than 50 miles from the Company’s current location; provided, however, that in each case above, Executive must first provide notice of the existence of the circumstances giving rise to a Constructive Termination within ninety (90) days of the initial existence of such circumstances and the Company must be provided with a period of thirty (30) days from the date of receipt of such notice to cure the circumstances giving rise to a Constructive Termination; provided further that the Company may notify Executive at any time prior to expiration of the cure period that it will not cure the circumstances, in which case the cure period shall end immediately upon such notification.

  • Environmental Definitions The following terms, as used herein, have the following meanings:

  • Proprietary Information Defined I understand that the term “Proprietary Information” in this Agreement means all information and any idea in whatever form, tangible or intangible, whether disclosed to or learned or developed by me, pertaining in any manner to the business of the Company or to the Company’s affiliates, consultants, or business associates, unless: (i) the information is or becomes publicly known through lawful means; (ii) the information was rightfully in my possession or part of my general knowledge prior to my employment by the Company; or (iii) the information is disclosed to me without confidential or proprietary restrictions by a third party who rightfully possesses the information (without confidential or proprietary restrictions) and did not learn of it, directly or indirectly, from the Company. I further understand that the Company considers the following information to be included, without limitation, in the definition of Proprietary Information: (A) schematics, techniques, employee suggestions, development tools and processes, computer printouts, computer programs, design drawings and manuals, electronic codes, formulas and improvements; (B) information about costs, profits, markets, sales, customers, prospective customers, customer contracts (including without limitation the terms and conditions of such customer contracts) and bids; (C) plans for business, marketing, future development and new product concepts; (D) customer lists, and distributor and representative lists; (E) all documents, books, papers, drawings, models, sketches, and other data of any kind and description, including electronic data recorded or retrieved by any means, that have been or will be given to me by the Company (or any affiliate of it), as well as written or verbal instructions or comments; (F) any information or material not described in (A)-(E) above which relate to the Company’s inventions, technological developments, “know how”, purchasing, accounts, merchandising, or licensing; (G) employee personnel files and information about employee compensation and benefits; and (H) any information of the type described in (A)-(G) above which the Company has a legal obligation to treat as confidential, or which the Company treats as proprietary or designates as confidential, whether or not owned or developed by the Company.

  • Provisions Solely to Define Relative Rights The provisions of this Article XII are and are intended solely for the purpose of defining the relative rights of the Holders of the Securities on the one hand and the holders of Senior Debt on the other hand. Nothing contained in this Article XII or elsewhere in this Indenture or in the Securities is intended to or shall (a) impair, as between the Company and the Holders of the Securities, the obligations of the Company, which are absolute and unconditional, to pay to the Holders of the Securities the principal of and any premium and interest (including any Additional Interest) on the Securities as and when the same shall become due and payable in accordance with their terms, (b) affect the relative rights against the Company of the Holders of the Securities and creditors of the Company other than their rights in relation to the holders of Senior Debt or (c) prevent the Trustee or the Holder of any Security (or to the extent expressly provided herein, the holder of any Preferred Security) from exercising all remedies otherwise permitted by applicable law upon default under this Indenture, including filing and voting claims in any Proceeding, subject to the rights, if any, under this Article XII of the holders of Senior Debt to receive cash, property and securities otherwise payable or deliverable to the Trustee or such Holder.

Time is Money Join Law Insider Premium to draft better contracts faster.